Table 3.
Treatment posology by population and by timepoint; the most frequent posology for each population at each time point is bolded
| Posology, N (%) | Rheumatology cohort | Gastroenterology cohort | |||
|---|---|---|---|---|---|
| RA | PsA | AS | CD | UC | |
| Baseline (M0) | |||||
| Naïve, N | 77 | 48 | 194 | 208 | 74 |
|
40 mg every week 40 mg Q2W 80 mg Q2W 40 mg Q3W 40 mg Q4W 80 mg at week 0 followed by 40 mg at week 2 160 mg at week 0 followed by 80 mg at week 2 |
3 (3.9%) 74 (96.1%) – – – – – |
– 48 (100%) – – – – – |
2 (1.0%) 190 (97.9%) 1 (0.5%) – 1 (0.5%) – – |
1 (0.5%) 18 (8.6%) – 1 (0.5%) 1 (0.5%) 10 (4.8%) 177 (84.6%) |
– 2 (2.7%) – – – 3 (4.1%) 69 (93.2%) |
| Switcheda, N | 39 | 29 | 112 | 108 | 13 |
|
40 mg every week 40 mg Q2W 80 mg Q2W 40 mg Q3W 40 mg Q4W 160 mg at week 0 followed by 80 mg at week 2 |
– 29 (76.3%) – 3 (7.9%) 6 (15.8%) – |
2 (6.9%) 22 (75.9%) – 3 (10.3%) 2 (6.9%) – |
4 (3.6%) 93 (83.0%) – 8 (7.1%) 7 (6.3%) – |
33 (25.6%) 73 (56.6%) 1 (0.8%) – – 1 (0.8%) |
2 (14.3%) 11 (78.6%) – – – – |
| Month 12 (M12) | |||||
| Naïve, N | 47 | 27 | 107 | 132 | 30 |
|
40 mg every week 40 mg Q2W 80 mg Q2W 40 mg Q3W 40 mg Q4W |
– 47 (100%) – – – |
3 (11.1%) 24 (88.9%) – – – |
4 (3.7%) 100 (93.5%) – 1 (0.9%) 2 (1.9%) |
26 (19.7%) 102 (77.3%) 4 (3.0%) – – |
10 (33.3%) 17 (56.7%) 2 (6.7%) – 1 (3.3%) |
| Switcheda, N | 25 | 17 | 61 | 66 | 6 |
|
40 mg every week 40 mg Q2W 80 mg Q2W 40 mg Q3W 40 mg Q4W |
1 (4.0%) 18 (72.0%) – 1 (4.0%) 5 (20.0%) |
1 (5.9%) 12 (70.6%) – 2 (11.8%) 2 (11.8%) |
5 (8.2%) 45 (73.8%) – 8 (13.1%) 3 (4.9%) |
28 (42.5%) 36 (54.5%) 1 (1.5%) 1 (1.5%) – |
1 (16.7%) 5 (83.3%) – – – |
AS ankylosing spondylitis, CD Crohn’s disease, CRP C-reactive protein, PsA psoriatic arthritis, Q2W every 2 weeks, Q3W every 3 weeks, Q4W every 4 weeks, RA rheumatoid arthritis, UC ulcerative colitis
aBoth from reference and from biosimilar adalimumab